Analyst Ratings for ACADIA Pharmaceuticals
Portfolio Pulse from Benzinga Insights
In the last quarter, ACADIA Pharmaceuticals (NASDAQ:ACAD) received 2 bullish, 3 somewhat bullish, and 4 indifferent analyst ratings. The average 12-month price target for the company is $25.29, up 19.01% from the previous average of $21.25.
June 14, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ACADIA Pharmaceuticals received mixed analyst ratings in the last quarter, with an average 12-month price target of $25.29, a 19.01% increase from the previous average.
The article provides an overview of analyst ratings for ACADIA Pharmaceuticals in the last quarter. While there are both bullish and somewhat bullish ratings, there are also indifferent ratings, indicating a mixed outlook. The average 12-month price target has increased by 19.01%, which may suggest potential growth, but the mixed ratings make it difficult to predict a clear short-term price direction.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100